STOCK TITAN

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Arcus Biosciences, Inc. (NYSE:RCUS) has granted options to purchase 31,350 shares and restricted stock units for 15,675 shares to twelve new employees. The options have an exercise price of $21.50, based on the closing price from May 9, 2022. This move is part of the company's 2020 Inducement Plan, approved in January 2020. Arcus is focused on developing innovative cancer therapies and has six investigational medicines in clinical studies targeting various cancer-related pathways.

Positive
  • Granting of 31,350 stock options and 15,675 restricted stock units to attract new talent.
  • Exercise price of $21.50 aligns with May 9, 2022 market value.
Negative
  • None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted twelve new employees options to purchase a total of 31,350 shares of the Company’s common stock at an exercise price per share of $21.50, which was the closing price on May 9, 2022, and restricted stock units to acquire a total of 15,675 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Inducement PR

Source: Arcus Biosciences

Investor and Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

What did Arcus Biosciences announce regarding employee compensation on May 9, 2022?

Arcus Biosciences granted stock options and restricted stock units to twelve new employees as part of its inducement plan.

What is the exercise price for the stock options granted by Arcus Biosciences?

The stock options have an exercise price of $21.50.

How many shares were included in the compensation package for new employees at Arcus Biosciences?

The compensation package included options for 31,350 shares and restricted stock units for 15,675 shares.

What is the purpose of the 2020 Inducement Plan at Arcus Biosciences?

The 2020 Inducement Plan is designed to attract and retain talent through equity awards.

Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Latest News

RCUS Stock Data

1.41B
54.37M
40.6%
60.08%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD